Last reviewed · How we verify
NCT03632018: HEART-PLAY
Heart Exercise And Resistance Training - Peer Lead ActivitY
NA trial testing HEART-PLAY in Cardiovascular Diseases in 295 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | University of California, San Diego |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 295 |
| Start date | 22 August 2018 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- HEART-PLAY
- Standard Cardiac Rehabilitation
Conditions studied
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
University of California, San Diego
Who can join
18 and older, any sex, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Numerous studies show that regular physical activity / exercise significantly improves exercise tolerance as well as clinical outcomes in cardiovascular disease (CVD). Exercise as a reliable adjunctive intervention, however, remains limited due to poor short- as well as long-term adherence. The study examines the effectiveness of the peer-led Heart Exercise And Resistance Training - Peer Lead ActivitY (HEART-PLAY) intervention to significantly sustain exercise adherence among CR patients, as compared a standard CR intervention. In a rigorous cluster randomized controlled trial at the UCSD Step Family Cardiovascular Rehabilitation and Wellness Center, the study assesses the HEART-PLAY intervention program in 264 socioeconomically and ethnically diverse women and men 18+ years old who have been referred to standard CR. Participants in the HEART-PLAY and in the STANDARD CR programs will both participate in 36 sessions of CR across approximately 12 weeks, as prescribed by their physician. Participants in HEART-PLAY will additionally receive peer and staff leadership, self-monitoring tools and feedback, group education and materials, and motivational, goal-setting, and relapse prevention counseling sessions. The study will demonstrate that the peer-led HEART-PLAY program based in the clinic setting will significantly enhance the primary study endpoint of adherence to 150 min/week of moderate physical activity/week.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Social network interventions to support cardiac rehabilitation and secondary prevention in the management of people with heart disease.
Purcell C, Dibben G, Hilton Boon M, Matthews L, et al · · 2023 · cited 17× · PMID 37378598 · DOI 10.1002/14651858.cd013820.pub2
Verify or expand the search:
- PubMed search for NCT03632018
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Diseases
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT07426263 — Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation. · NA · active not recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other University of California, San Diego trials
Trials by the same sponsor.
- NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
- NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
- NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
- NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03632018 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
- Last refreshed: 9 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03632018.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing